ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 231 for:    "essential thrombocythemia"

Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03165734
Recruitment Status : Recruiting
First Posted : May 24, 2017
Last Update Posted : December 12, 2018
Sponsor:
Collaborator:
Covance
Information provided by (Responsible Party):
CTI BioPharma

Brief Summary:

This is a Bayesian adaptive dose-finding study in patients with primary or secondary myelofibrosis:

  1. who have failed therapy with ruxolitinib on the basis of intolerance or loss of efficacy,
  2. highly symptomatic (DIPSS risk score of Intermediate-1, Intermediate-2 or High Risk, and MPN-SAF TSS 2.0 of ≥10),
  3. and have splenomegaly (assessed by physical examination).

Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis

Intervention/treatment: Drug-Pacritinib

Phase: Phase 2


Condition or disease Intervention/treatment Phase
Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Drug: Pacritinib Phase 2

Detailed Description:

The study is designed to support a pacritinib dosage selection decision. Three dosages will be evaluated, with patients randomized 1:1:1 to pacritinib 100 mg QD, pacritinib 100 mg BID, or pacritinib 200 mg BID. Randomization will be stratified by baseline platelet count (≤50,000/µL; >50,000/µL and ≤100,000/µL; and >100,000/µL). Assigned treatment will continue until the patient experiences progressive disease, intolerable AEs, withdraws consent, or until the assigned treatment arm is closed. No study treatment crossover will be allowed. All patients should complete all visit procedures through Week 24, including patients who stop pacritinib treatment or have protocol-defined progressive disease prior to Week 24, unless patient withdraws consent, dies, undergoes splenic irradiation or splenectomy, or initiates any non-protocol-directed anti-myelofibrosis treatment. The maximum duration of trial participation for an individual patient will be approximately 36 months. The Following the Week 24 assessment, patients who are benefiting from therapy and who have not experienced progressive disease will be allowed to continue receiving pacritinib at the original randomized dose or following the dose recommendations of the Independent Data Monitoring Committee (IDMC), and will be followed for survival, efficacy and safety for up to 2.5 years.

The Sponsor will collect PK samples from all patients in each dosing arm at the end of Week 12 and Week 24 at the following timepoints: 0 hours (predose), 4 hours postdose (±10 minutes), and 8 hours postdose (±15 minutes). In addition, PD samples will be collected on Day 1 (Baseline), Week 12, and Week 24 at 0 hours (predose). DNA samples will also be collected for analysis of mutations associated with myelofibrosis at baseline and Week 24.

This study will utilize planned frequent monitoring by an IDMC. The first meeting will occur once 18 patients have been randomized and will meet approximately quarterly thereafter. To minimize the patient exposure to minimally effective dosages, an interim analysis of the primary efficacy and safety data will be performed to allow an earlier decision to discontinue an arm that is unlikely to achieve at least 10% SVR at Week 24. The interim analysis will be performed when 6 patients per arm have completed the Week 12 evaluations and have evaluable spleen volume data by MRI or CT.

IDMC will review efficacy and safety data, including interim analysis, and make recommendations on:

  1. Closing treatment arm(s) and expanding enrollment in remaining treatment arm(s)
  2. Pausing enrollment due to cardiac or hemorrhage adverse events
  3. Dosage for further clinical studies

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Actual Study Start Date : June 26, 2017
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : March 1, 2019


Arm Intervention/treatment
Experimental: Pacritinib 100 mg QD
Pacritinib 100 mg (1 capsule) QD orally, at the same time of day, with or without food
Drug: Pacritinib
Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsules contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base

Experimental: Pacritinib 100 mg BID
Pacritinib 100 mg (1 capsule) BID orally, at the same time of day, with or without food
Drug: Pacritinib
Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsules contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base

Experimental: Pacritinib 200 mg BID
Pacritinib 200 mg (2 capsules) BID orally, at the same time of day, with or without food
Drug: Pacritinib
Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsules contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base




Primary Outcome Measures :
  1. Spleen volume [ Time Frame: 24 weeks ]
    The primary efficacy variable for dosage selection is the percent reduction in spleen volume from baseline as measured by MRI or CT. For evaluation as part of the dose-response relationship will include the percentage of patients who achieve at least 35% reduction in spleen volume


Secondary Outcome Measures :
  1. Percentage of patients with CTCAE grade ≥3 cardiac AEs, CTCAE grade ≥3 hemorrhage AEs, CTCAE grade ≥4 thrombocytopenia toxicity, or CTCAE grade ≥4 anemia toxicity [ Time Frame: Day 0 through the patient's last day of study participation, approximately 8 months ]
    The safety population is defined as all randomized patients who received at least one dose of study treatment. For screened patients who are not randomized, only SAEs occurring between the time of informed consent and determination of screen failure are to be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008)
  2. DIPSS Intermediate-1, Intermediate -2, or High risk (Passamonti et al 2010)
  3. Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:

    1. Treatment for ≥3 months with inadequate efficacy response defined as <10% spleen volume reduction by MRI or <30% decrease from baseline in spleen length by physical examination or regrowth to these parameters following an initial response; and/or
    2. Treatment for ≥28 days complicated by either

    i. Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months)

    ii. National Cancer Institute (NCI) CTCAE grade ≥3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of <20 mg BID

  4. Palpable splenomegaly ≥5 cm below the lower costal margin in the midclavicular line as assessed by physical examination
  5. TSS of ≥10 on the MPN-SAF TSS 2.0 or patients with a single symptom score of ≥5 or two symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats
  6. Age ≥18 years old
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  8. Peripheral blast count of <10%
  9. Absolute neutrophil count of >500/µL
  10. Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), ≤3 × the upper limit of normal (ULN) (AST/ALT ≤5 × ULN if transaminase elevation is related to MF), direct bilirubin ≤4× ULN, and creatinine ≤2.5 mg/dL
  11. Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of ≤1.5 × ULN
  12. Left ventricular cardiac ejection fraction of ≥45% by echocardiogram or multigated acquisition (MUGA) scan
  13. If fertile, willing to use effective birth control methods during the study
  14. Willing to undergo and able to tolerate frequent MRI or CT assessments during the study
  15. Able to understand and willing to complete symptom assessments using a patient reported outcomes instrument
  16. Provision of informed consent

Exclusion Criteria:

  1. Life expectancy <6 months
  2. Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing to complete allo-SCT
  3. History of splenectomy or planning to undergo splenectomy
  4. Splenic irradiation within the last 6 months
  5. Previously treated with pacritinib
  6. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of ≤100 mg per day, within the last 2 weeks
  7. Treatment with a strong CYP3A4 inhibitor or a strong cytochrome P450 inducer within the last 2 weeks
  8. Treatment with medications that can prolong the QTc interval within the last 2 weeks
  9. Treatment with an experimental therapy within the last 28 days
  10. Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
  11. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety.
  12. New York Heart Association Class II, III, or IV congestive heart failure
  13. Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
  14. QTc prolongation >450 ms or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)
  15. Any gastrointestinal or metabolic condition that could interfere with absorption of oral medication
  16. Inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation
  17. Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma
  18. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection or psychiatric illness or social situation that, in the judgment of the treating physician, would limit compliance with study requirements
  19. Known seropositivity for human immunodeficiency virus
  20. Known active hepatitis A, B, or C virus infection
  21. Women who are pregnant or lactating
  22. Concurrent enrollment in another interventional trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03165734


Contacts
Contact: Debra Jones 206-282-7100 djones@ctibiopharma.com
Contact: Monica Gelder 206-282-7100 mgelder@ctibiopharma.com

  Show 59 Study Locations
Sponsors and Collaborators
CTI BioPharma
Covance

Responsible Party: CTI BioPharma
ClinicalTrials.gov Identifier: NCT03165734     History of Changes
Other Study ID Numbers: PAC203
First Posted: May 24, 2017    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by CTI BioPharma:
Post-essential Thrombocythemia Myelofibrosis
myelofibrosis
pacritinib
Post-polycythemia Vera Myelofibrosis
Ruxolitinib
Bone Marrow Disease
Hematologic Diseases
Blood Platelet Disorders
Hemorrhagic Disorders
Splenomegaly
Anemia
Spleen volume
Spleen

Additional relevant MeSH terms:
Primary Myelofibrosis
Polycythemia
Polycythemia Vera
Thrombocytosis
Thrombocythemia, Essential
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Bone Marrow Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Neoplasms
Blood Platelet Disorders
Blood Coagulation Disorders
Hemorrhagic Disorders